Infection Control & Hospital Epidemiology
Conflicts of interest. Dr Kaplan serves as the primary investigator (PI) on an investigator-initiated clinical trial sponsored by Allergan as well as the site PI of a clinical trial sponsored by Merck. Dr McNeil serves as a co-investigator on these studies, neither of which is directly related to the present
work.Noauthors have significant financial conflicts of interest.
Supplementary material. To view supplementary material for this article, please visit
https://doi.org/10.1017/ice.2019.3
References
1. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003;22:686–691.
2. Murray MT, Krishnamurthy G, Corda R, et al. Surgical site infections and bloodstreaminfections in infants after cardiac surgery. J Thorac Cardiovasc Surg 2014;148:259–265.
3. Blackburn RM, Henderson KL, Minaji M, Meuller-Pedobdy B, Johnson AP, Sharland M. Exploring the epidemioogy of hospital-acquired bloodstream infections in children in England (January 2009–March 2010) by linkage of national hospital admissions and microbiological databases. J Pediatr Infect Dis Soc 2012;1:284–292.
4. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007;167:2073–2079.
5. ClimoMW,Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bath- ing on hospital-acquired infection. N Engl J Med 2013;368:533–542.
6. Lee BY, Bartsch SM, Wong KF, et al. Beyond the intensive care unit (ICU): countywide impact of universal ICU Staphylococcus aureus decolonization. Am J Epidemiol 2016;183:480–489.
7. MilstoneAM,Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 2013;381:1099–1106.
8. Toltzis P, O’Riordan M, Cunningham DJ, et al. A statewide collaborative to reduce pediatric surgical site infections. Pediatrics 2014;134: e1174–e1180.
9. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. 1999;20:250–280.
Infect Control Hosp Epidemiol
10. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52:e162–e193.
11. Yokoe DS, Anderson DJ, Berenholtz SM, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol 2014;35 suppl 2:S21–S31.
12. Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA. Efflux- mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar-transport proteins. Mol Microbiol 1990;4:2051–2062.
13. Brown MH, Skurray RA. Staphylococcal multidrug efflux protein QacA. J Mol Microbiol Biotechnol 2001;3:163–170.
14. Paulsen IT, Brown MH, Littlejohn TG, Mitchell BA, Skurray RA. Multidrug resistance proteinsQacAand QacB from Staphylococcus aureus: membrane topology and identification of residues involved in substrate specificity. Proc Natl Acad Sci USA 1996;93:3630–3635.
15. Littlejohn TG, DiBerardino D, Messerotti LJ, Spiers SJ, Skurray RA. Structure and evolution of a family of genes encoding antiseptic and disin- fectant resistance in Staphylococcus aureus. Gene 1991;101:59–66.
16. SmithK, GemmellCG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and com- munity-acquired MRSA isolates. J Antimicrob Chemother 2008;61:78–84.
17. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus infections in pediatric oncology patients: high rates of antimicrobial resistance, antiseptic tolerance and complications. Pediatr Infect Dis J 2013;32:124–128.
339
18. Suwantarat N, Carroll KC, Tekle T, et al. High prevalence of reduced chlorhexidine susceptibility in organisms causing central line-associated bloodstream infections. Infect Control Hosp Epidemiol 2014;35: 1183–1186.
19. Warren DK, Prager M, Munigala S, et al. Prevalence of qacA/B genes and mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) isolates in the setting of chlorhexidine bathing without mupirocin. Infect Control Hosp Epidemiol 2016;37:590–597.
20. McNeil JC, Kok EY, Vallejo JG, et al. Clinical and molecular features of decreased chlorhexidine susceptibility among nosocomial Staphylococcus aureus isolates at Texas Children’s Hospital. Antimicrob Agents Chemother 2015;60:1121–1128.
21. McNeil JC, Hulten KG, Mason EO, Kaplan SL. Impact of health care expo- sure on genotypic antiseptic tolerance in Staphylococcus aureus infections in a pediatric population. Antimicrob Agents Chemother 2017;61:e00223–17. doi: 10.1128/AAC.00223-17.
22. Fritz SA, Hogan PG, Camins BC, et al. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 2013;57: 559–568.
23. Johnson JG, Saye EJ, Jimenez-Truque N, et al. Frequency of disinfectant re- sistance genes in pediatric strains of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2013;34:1326–1327.
24. Reich PJ, Boyle MG, Hogan PG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains in the neonatal intensive care unit: an infection prevention and patient safety challenge. Clin Microbiol Infect 2016;22:645–648.
25. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol 2013;33:768–771.
26. Johnson J, Bracken R, Tamma PD, Aucott SW, Bearer C, Milstone AM. Trends in chlorhexidine use inUSneonatal intensive care units: results from a follow-up national survey. Infect Control Hosp Epidemiol 2016;37: 1116–1118.
27. Hijazi K, Mukhopadhya I, Abbott F, et al. Susceptibility to chlorhexidine amongst multidrug-resistant clinical isolates of Staphylococcus epidermidis from bloodstream infections. Int J Antimicrob Agents 2016;48:86–90.
28. Bischoff M, Bauer J, Preikschat P, Schwaiger K, Molle G, Holzel C. First detection of the antiseptic resistance gene qacA/B in Enterococcus faecalis. Microb Drug Resist 2012;18:7–12.
29. Prag G, Falk-Brynhildsen K, Jacobsson S, Hellmark B, Unemo M, Soderquist B. Decreased susceptibility to chlorhexidine and prevalence of disinfectant resistance genes among clinical isolates of Staphylococcus epi- dermidis. APMIS 2014;122:961–967.
30. Lepainteur M, Royer G, Bourrel AS, et al. Prevalence of resistance to anti- septics and mupirocin among invasive coagulase-negative staphylococci from very preterm neonates in NICU: the creeping threat? J Hosp Infect 2013;83:333–336.
31. Soma VL, Qin X, Zhou C, Adler A, Berry JE, Zerr DM. The effects of daily chlorhexidine bathing on cutaneous bacterial isolates: a pilot study. Infect Drug Resist 2012;5:75–78.
32. Zhang M, O’Donoghue MM, Ito T, Hiramatsu K, Boost MV. Prevalence of antiseptic-resistance genes in Staphylococcus aureus and coagulase- negative staphylococci colonising nurses and the general population in Hong Kong. J Hosp Infect 2011;78:113–117.
33. Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of com- munity onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J 2006;25:349–353.
34. Wang SH, Hines L, van Balen J, et al. Molecular and clinical characteristics of hospital and community onset methicillin-resistant Staphylococcus aureus strains associated with bloodstream infections. J Clin MIcrobiol 2015;53:1599–1608.
35. Hulten KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children’s Hospital, 2001–2007. Infect Control Hosp Epidemiol 2010;31:183–190.
36. Mermel LA, AllonM, Bouza E, et al. Clinical practice guidelines for the diag- nosis and management of intravascular catheter-related infection: 2009
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
